APA (7th ed.) Citation

B, W., R, B., G, C., MS, F., TP, L., X, M., . . . JS, W. (2022). Ocrelizumab treatment for relapsing-remitting multiple sclerosis after a suboptimal response to previous disease-modifying therapy: A nonrandomized controlled trial. Multiple sclerosis (Houndmills, Basingstoke, England), 28(5), 790. https://doi.org/10.1177/13524585211035740

Chicago Style (17th ed.) Citation

B, Weinstock-Guttman, et al. "Ocrelizumab Treatment for Relapsing-remitting Multiple Sclerosis After a Suboptimal Response to Previous Disease-modifying Therapy: A Nonrandomized Controlled Trial." Multiple Sclerosis (Houndmills, Basingstoke, England) 28, no. 5 (2022): 790. https://doi.org/10.1177/13524585211035740.

MLA (9th ed.) Citation

B, Weinstock-Guttman, et al. "Ocrelizumab Treatment for Relapsing-remitting Multiple Sclerosis After a Suboptimal Response to Previous Disease-modifying Therapy: A Nonrandomized Controlled Trial." Multiple Sclerosis (Houndmills, Basingstoke, England), vol. 28, no. 5, 2022, p. 790, https://doi.org/10.1177/13524585211035740.